Risk-adapted chemotherapy in childhood medulloblastoma

References

• Blaney SM, Kun LE, Hunter J et al. Tumors of the central nervous system. In: Principles and Practice of Pediatric Oncology (5th Edition). Pizzo PA, Poplack DG (Eds). Lippincott, Williams and Wilkins, PA, USA, 786–864 (2006).
   Google Scholar
• Akyuz C, Varan A, Kupeli S et al. Medulloblastoma in children: a 32-year experience from a single institution. J. Neuro-Oncol.90, 99–103 (2008).
   PubMedGoogle Scholar
• Matsutani M. Chemoradiotherapy for brain tumors: current status and perspectives. Int. J. Clin. Oncol.9, 471–474 (2004).
   PubMedGoogle Scholar
• Crawford JR, MacDonald T, Packer RJ. Medulloblastoma in childhood: new biological advances. Lancet Neurol.6, 1073–1085 (2007).
   PubMed Web of Science ®Google Scholar
• Kombogiorgas D, Sgouros S, Walsh AR et al. Outcome of children with posterior fossa medulloblastoma: a single institution experience over the decade 1994–2003. Childs Nerv. Syst.23, 399–405 (2007).
   PubMed Web of Science ®Google Scholar
• Kortmann RD, Kühl J, Timmermann B et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT ’91. Int. J. Radiation Oncology Biol. Phys.46, 269–279 (2000).
   PubMed Web of Science ®Google Scholar
• Packer RJ, Goldwein J, Nicholson HS et al. Treatment of children with medulloblastoma with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group Study. J. Clin. Oncol.17, 2127–2136 (1999).
   PubMed Web of Science ®Google Scholar
• Packer RJ, Sutton LN, Elterman R et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU and vincristine chemotherapy. J. Neurosurg.81, 690–698 (1994).
   PubMed Web of Science ®Google Scholar
• Paulino AC, Melian E. Medulloblastoma and supratentorial primitive neuroectodermal tumors: an institutional experience. Cancer86, 142–148 (1999).
   PubMed Web of Science ®Google Scholar
• Zeltzer PM, Boyett JM, Finlay JL et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized Phase III study. J. Clin. Oncol.17, 832–845 (1999).
   PubMed Web of Science ®Google Scholar
• Packer RJ, Rood B, MacDonald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr. Neurosurg.39, 60–67 (2003).
   PubMedGoogle Scholar
• Caputy AJ, McCullough DC, Manz HJ, Patterson K, Hammock MK. A review of the factors influencing the prognosis of medulloblastoma. J. Neurosurg.66, 80–87 (1987).
   PubMedGoogle Scholar
• Jenkin D, Shabanah MA, Shail EA et al. Prognostic factors for medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys.47, 573–584 (2000).
   PubMed Web of Science ®Google Scholar
• Polkinghorn WR, Tarbell NJ. Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat. Clin. Prac. Oncol.4, 295–304 (2007).
   PubMedGoogle Scholar
• Brown RC, Gunderson L, Plenk HP. Medulloblastoma: a review of the LDS hospital experience. Cancer40, 56–60 (1977).
   PubMed Web of Science ®Google Scholar
• Ater JL, van Eys J, Woo SY, Moore B 3rd, Copeland DR, Bruner J. MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children. J. Neuro-Oncol.32, 243–252 (1997).
   PubMed Web of Science ®Google Scholar
• Castello MA, Clerico A, Deb G, Dominici C, Fidani P, Donfrancesco A. High-dose carboplatin in combination with etoposide (JET regimen) for childhood brain tumors. Am. J. Pediatr. Hematol. Oncol.12, 297–300 (1990).
   PubMedGoogle Scholar
• Evans AE, Jenkin RD, Sposto R et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J. Neurosurg.72, 572–582 (1990).
   PubMed Web of Science ®Google Scholar
• Tait DM, Thornton-Jones H, Bloom HJG, Lemerle J, Morris-Jones P. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur. J. Cancer26, 464–469 (1990).
   PubMed Web of Science ®Google Scholar
• Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD, Hammond GD. Carboplatin in childhood brain tumors: a children’s cancer study group Phase II trial. Cancer66, 2465–2469 (1990).
   PubMed Web of Science ®Google Scholar
• Kovnar EH, Kellie SJ, Horowitz ME et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a Phase II study. J. Clin. Oncol.8, 330–336 (1990).
   PubMed Web of Science ®Google Scholar
• Pendergrass TW, Milstein JM, Geyer JR et al. Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy. J. Clin. Oncol.5, 1221–1231 (1987).
   PubMed Web of Science ®Google Scholar
• Geyer JR, Pendergrass TW, Milstein JM, Bleyer WA. Eight drugs in one day chemotherapy in children with brain tumors: a critical toxicity appraisal. J. Clin. Oncol.6, 996–1000 (1988).
   PubMedGoogle Scholar
• Packer RJ, Gajjar A, Vezina G et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J. Clin. Oncol.24, 4202–4208 (2006).
   PubMed Web of Science ®Google Scholar
• Fossati P, Ricardi U, Orecchia R. Pediatric medulloblastoma: toxicity of current treatment and potential role of protontherapy. Cancer Treatment Rev.35, 79–96 (2009).
   PubMed Web of Science ®Google Scholar
• Tucker MA, D’Angio GJ, Boice JD et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N. Engl. J. Med.317, 588–593 (1987).
   PubMed Web of Science ®Google Scholar
• Bailey CC, Gnekow A, Wellek S et al. Prospective randomized trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Pediatric Oncology (SIOP) and the German Society of Pediatric Oncology (GPO): SIOP II. Med. Pediatr. Oncol.25, 166–178 (1995).
   PubMedGoogle Scholar
• Oyharcabal-Bourden V, Kalifa C, Gentet JC et al. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. J. Clin. Oncol.23, 4726–4734 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor RE, Bailey CC, Robinson K et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 study. J. Clin. Oncol.21, 1581–1591 (2003).
   PubMed Web of Science ®Google Scholar
• Verlooy J, Mosseri V, Bracard S et al. Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study. Eur. J. Cancer42, 3004–3014 (2006).
   PubMed Web of Science ®Google Scholar
• Taylor RE, Bailey CC, Robinson KJ et al. Outcome for patients with metastatic (M2–3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur. J. Cancer41, 727–734 (2005).
   PubMed Web of Science ®Google Scholar
• Prados MD, Edwards MSB, Chang SM et al. Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a Phase II study. Int. J. Radiat. Oncol. Biol. Phys.43, 279–285 (1999).
   PubMed Web of Science ®Google Scholar
• Tabori U, Sung L, Hukin J et al. Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a Canadian Pediatric Brain Tumor Consortium Study. Cancer103, 1874–1880 (2005).
   PubMed Web of Science ®Google Scholar
• Kalifa C, Grill J. The therapy of infantile malignant brain tumors: current status? J. Neuro-Oncol.75, 279–285 (2005).
   PubMed Web of Science ®Google Scholar
• Duffner PK, Horowitz ME, Krischer JP et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N. Engl. J. Med.328, 1725–1731 (1993).
   PubMed Web of Science ®Google Scholar
• Jakacki RI, Feldman H, Jamison C, Boaz JC, Luerssen TG, Timmerman R. A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys.60, 531–536 (2004).
   PubMed Web of Science ®Google Scholar
• Grill J, Sainte-Rose C, Jouvet A et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol.6, 573–580 (2005).
   PubMed Web of Science ®Google Scholar
• White L, Kellie S, Gray E et al. Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: promising initial response to a VETOPEC-based regimen: a study of the Australian and New Zealand Children’s Cancer Study Group (ANZCCSG). J. Pediatr. Hemat. Oncol.20, 125–130 (1998).
   PubMed Web of Science ®Google Scholar
• Geyer JR, Sposto R, Jennings M et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the children’s cancer group. J. Clin. Oncol.23, 7621–7631 (2005).
   PubMed Web of Science ®Google Scholar
• Gajjar A, Mulhern RK, Heideman RL et al. Medulloblastoma in very young children: Outcome of definitive craniospinal irradiation following incomplete response to chemotherapy. J. Clin. Oncol.12, 1212–1216 (1994).
   PubMedGoogle Scholar
• Rutkowski S, Bode U, Deinlein F et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N. Engl. J. Med.352, 978–986 (2005).
   PubMed Web of Science ®Google Scholar
• Thorarinsdottir HK, Rood B, Kamani N et al. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue. Pediatr. Blood Cancer48, 278–284 (2007).
   PubMedGoogle Scholar
• Chi SN, Gardner SL, Levy AS et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J. Clin. Oncol.22, 4881–4887 (2004).
   PubMed Web of Science ®Google Scholar
• Dhall G, Grodman H, Ji L et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the ‘Head Start’ I and II protocols. Pediatr. Blood Cancer50, 1169–1175 (2008).
   PubMed Web of Science ®Google Scholar
• Varan A, Akalan N, Söylemezoğlu F et al. Central nervous system tumors in patients under 3 years of age: treatment results of a single institute. Pediatr. Neurosurg.42, 89–94 (2006).
   PubMedGoogle Scholar
• Rivera-Luna R, López E, Rivera-Marquez H et al. Survival of children under 3 years old with medulloblastoma: a study from the Mexican Cooperative Group for Childhood Malignancies (AMOHP). Child Nerv. Syst.18, 38–42 (2002).
   PubMedGoogle Scholar
• Garre ML, Cama A, Bagnasco F et al. Medulloblastoma variants: age-dependent occurrence and relation to Gorlin syndrome-a new clinical perspective. Clin. Cancer Res.15, 2463–2471 (2009).
   PubMed Web of Science ®Google Scholar
• Ridola V, Grill J, Doz F et al. High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy. Cancer110, 156–163 (2007).
   PubMed Web of Science ®Google Scholar
• Valteau-Couanet D, Fillipini B, Benhamou E et al. High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy. Bone Marrow Transplant36, 939–945 (2005).
   PubMed Web of Science ®Google Scholar
• Perez-Martinez A, Lassaletta A, Gonzalez-Vicent M, Sevilla J, Díaz MA, Madero L. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. J. Neuro-Oncol.71, 33–38 (2005).
   PubMed Web of Science ®Google Scholar
• Gajjar A, Chintagumpala M, Ashley D et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial . Lancet Oncol.7, 813–820 (2006).
   PubMed Web of Science ®Google Scholar
• Stewart CF, Iacono LC, Chintagumpala M et al. Results of a Phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J. Clin. Oncol.22, 3357–3365 (2004).
   PubMedGoogle Scholar
• Sung KW, Yoo KH, Cho EJ et al. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr. Blood Cancer48, 408–415 (2007).
   PubMedGoogle Scholar
• Dunkel IJ, Gardner SL, Garvin JH, Goldman S, Shi W, Finlay JL. High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. Neuro-Oncol.12, 297–303 (2010).
   PubMed Web of Science ®Google Scholar
• Baruchel S, Diezi M, Hargrave D et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent pediatric brain tumors. Eur. J. Cancer42, 2335–2342 (2006).
   PubMed Web of Science ®Google Scholar
• Fouladi M, Blaney SM, Poussaint TY et al. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer107, 2291–2297 (2006).
   PubMed Web of Science ®Google Scholar
• Kieran MW, Packer RJ, Onar A et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a pediatric brain consortium study. J. Clin. Oncol.25, 3137–3143 (2007).
   PubMed Web of Science ®Google Scholar
• Spiller S, Ravanpay AC, Hahn AW, Olson JM. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J. Neurooncol.79, 259–270 (2006).
   PubMed Web of Science ®Google Scholar
• Warren K, Jakacki R, Widemann B et al. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children’s Oncology Group. Cancer Chemother. Pharmacol.58, 343–347 (2006).
   PubMed Web of Science ®Google Scholar